Bayer has decided to combine its pharmaceutical research and development activities under one leadership. The unit will combine all research and development activities for the therapeutic areas of cardiology, gynecology, ophthalmology, hematology as well as oncology research within the company’s Pharmaceuticals Division.

Joerg Moeller, currently head of development at Bayer’s Pharmaceuticals Division, will become head of research and development, effective January 1, 2018. Andreas Busch, currently head of drug discovery within the Pharmaceuticals Division of Bayer, has decided to pursue a new career opportunity at another company.

Moeller has been head of development at the company’s Pharmaceuticals Division since February 2014. Moeller’s career at Bayer began in 1993 in the Clinical Research International Department, where he worked as a clinical project manager at the Pharmaceutical Research Center in Wuppertal, Germany. This was followed by various managerial positions with increasing responsibility in clinical development in the US and Canada. In 2001, Moeller returned to Germany and was appointed vice president of Strategic Drug Development Cardiovascular. From 2002 to 2003, he was in charge of the Global Clinical Strategy Department of the former Bayer HealthCare’s Pharmaceuticals Division.

He was then appointed head of Global Clinical Development, in which capacity he was based in the US. In his new role, Moeller will be a member of the company’s Pharmaceutical Executive Committee.           

Source: Bayer